A new strategy for the treatment of advanced ovarian cancer: utilizing nanotechnology to regulate the tumor microenvironment
Advanced ovarian cancer (AOC) is prone to recurrence, which can be attributed to drug resistance. Drug resistance may be related to the tumor microenvironment (TME), including the immune and non-immune TME. In the immune TME, the immune effector cells such as dendritic cells (DCs), M1-like tumor-ass...
Saved in:
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2025-02-01
|
| Series: | Frontiers in Immunology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fimmu.2025.1542326/full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1823856631078715392 |
|---|---|
| author | Zixuan Xiong Yichun Huang Shulong Cao Xuqun Huang Haiyuan Zhang |
| author_facet | Zixuan Xiong Yichun Huang Shulong Cao Xuqun Huang Haiyuan Zhang |
| author_sort | Zixuan Xiong |
| collection | DOAJ |
| description | Advanced ovarian cancer (AOC) is prone to recurrence, which can be attributed to drug resistance. Drug resistance may be related to the tumor microenvironment (TME), including the immune and non-immune TME. In the immune TME, the immune effector cells such as dendritic cells (DCs), M1-like tumor-associated macrophages (M1-TAMs), and T cells are inhibited. In contrast, immunosuppressive cells such as M2-like tumor-associated macrophages (M2-TAMs), myeloid-derived suppressor cells (MDSCs), and regulatory T cells (Tregs) are activated. These changes make it difficult to produce immune effects and affect the efficacy of chemo-immunotherapy. In the non-immune TME, mechanisms such as apoptosis inhibition, DNA damage response (DDR), and epithelial-mesenchymal transition (EMT) can promote tumor growth, metastasis, and drug resistance. Despite the challenges posed by the TME in the treatment of AOC, the unique biological advantages of nanoparticles (NPs) make it possible to regulate the TME. NPs can stimulate the immune responses of M1-TAMs, DCs, and T cells while reducing the infiltration of immune suppressive cells such as M2-TAMs and Tregs, thereby regulating the AOC immune TME. In addition, NPs can regulate the non-immune TME by reducing apoptosis in AOC cells, inhibiting homologous recombination (HR) repair, reversing EMT, and achieving the effect of reversing drug resistance. In summary, the application of NPs provides some new venues for clinical treatment in AOC. |
| format | Article |
| id | doaj-art-f1fbbc59d4ec48bdbb3c28a0a4daabc1 |
| institution | Kabale University |
| issn | 1664-3224 |
| language | English |
| publishDate | 2025-02-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Immunology |
| spelling | doaj-art-f1fbbc59d4ec48bdbb3c28a0a4daabc12025-02-12T07:25:46ZengFrontiers Media S.A.Frontiers in Immunology1664-32242025-02-011610.3389/fimmu.2025.15423261542326A new strategy for the treatment of advanced ovarian cancer: utilizing nanotechnology to regulate the tumor microenvironmentZixuan Xiong0Yichun Huang1Shulong Cao2Xuqun Huang3Haiyuan Zhang4School of Basic Medicine, Health Science Center, Yangtze University, Jingzhou, ChinaDepartment of Oncology, The First Affiliated Hospital of Kunming Medical University, Kunming, ChinaDepartment of Pathology, Songzi People’s Hospital, Jingzhou, ChinaDepartment of Medical Oncology, Huangshi Central Hospital, Affiliated Hospital of Hubei Polytechnic University, Huangshi, ChinaSchool of Basic Medicine, Health Science Center, Yangtze University, Jingzhou, ChinaAdvanced ovarian cancer (AOC) is prone to recurrence, which can be attributed to drug resistance. Drug resistance may be related to the tumor microenvironment (TME), including the immune and non-immune TME. In the immune TME, the immune effector cells such as dendritic cells (DCs), M1-like tumor-associated macrophages (M1-TAMs), and T cells are inhibited. In contrast, immunosuppressive cells such as M2-like tumor-associated macrophages (M2-TAMs), myeloid-derived suppressor cells (MDSCs), and regulatory T cells (Tregs) are activated. These changes make it difficult to produce immune effects and affect the efficacy of chemo-immunotherapy. In the non-immune TME, mechanisms such as apoptosis inhibition, DNA damage response (DDR), and epithelial-mesenchymal transition (EMT) can promote tumor growth, metastasis, and drug resistance. Despite the challenges posed by the TME in the treatment of AOC, the unique biological advantages of nanoparticles (NPs) make it possible to regulate the TME. NPs can stimulate the immune responses of M1-TAMs, DCs, and T cells while reducing the infiltration of immune suppressive cells such as M2-TAMs and Tregs, thereby regulating the AOC immune TME. In addition, NPs can regulate the non-immune TME by reducing apoptosis in AOC cells, inhibiting homologous recombination (HR) repair, reversing EMT, and achieving the effect of reversing drug resistance. In summary, the application of NPs provides some new venues for clinical treatment in AOC.https://www.frontiersin.org/articles/10.3389/fimmu.2025.1542326/fulladvanced ovarian cancer (AOC)tumor microenvironment (TME)chemo-immunotherapydrug resistancenanotechnology |
| spellingShingle | Zixuan Xiong Yichun Huang Shulong Cao Xuqun Huang Haiyuan Zhang A new strategy for the treatment of advanced ovarian cancer: utilizing nanotechnology to regulate the tumor microenvironment Frontiers in Immunology advanced ovarian cancer (AOC) tumor microenvironment (TME) chemo-immunotherapy drug resistance nanotechnology |
| title | A new strategy for the treatment of advanced ovarian cancer: utilizing nanotechnology to regulate the tumor microenvironment |
| title_full | A new strategy for the treatment of advanced ovarian cancer: utilizing nanotechnology to regulate the tumor microenvironment |
| title_fullStr | A new strategy for the treatment of advanced ovarian cancer: utilizing nanotechnology to regulate the tumor microenvironment |
| title_full_unstemmed | A new strategy for the treatment of advanced ovarian cancer: utilizing nanotechnology to regulate the tumor microenvironment |
| title_short | A new strategy for the treatment of advanced ovarian cancer: utilizing nanotechnology to regulate the tumor microenvironment |
| title_sort | new strategy for the treatment of advanced ovarian cancer utilizing nanotechnology to regulate the tumor microenvironment |
| topic | advanced ovarian cancer (AOC) tumor microenvironment (TME) chemo-immunotherapy drug resistance nanotechnology |
| url | https://www.frontiersin.org/articles/10.3389/fimmu.2025.1542326/full |
| work_keys_str_mv | AT zixuanxiong anewstrategyforthetreatmentofadvancedovariancancerutilizingnanotechnologytoregulatethetumormicroenvironment AT yichunhuang anewstrategyforthetreatmentofadvancedovariancancerutilizingnanotechnologytoregulatethetumormicroenvironment AT shulongcao anewstrategyforthetreatmentofadvancedovariancancerutilizingnanotechnologytoregulatethetumormicroenvironment AT xuqunhuang anewstrategyforthetreatmentofadvancedovariancancerutilizingnanotechnologytoregulatethetumormicroenvironment AT haiyuanzhang anewstrategyforthetreatmentofadvancedovariancancerutilizingnanotechnologytoregulatethetumormicroenvironment AT zixuanxiong newstrategyforthetreatmentofadvancedovariancancerutilizingnanotechnologytoregulatethetumormicroenvironment AT yichunhuang newstrategyforthetreatmentofadvancedovariancancerutilizingnanotechnologytoregulatethetumormicroenvironment AT shulongcao newstrategyforthetreatmentofadvancedovariancancerutilizingnanotechnologytoregulatethetumormicroenvironment AT xuqunhuang newstrategyforthetreatmentofadvancedovariancancerutilizingnanotechnologytoregulatethetumormicroenvironment AT haiyuanzhang newstrategyforthetreatmentofadvancedovariancancerutilizingnanotechnologytoregulatethetumormicroenvironment |